{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T13:24:33Z","timestamp":1788009873664,"version":"build-2784847793"},"reference-count":120,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.blre.2020.100714","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T19:22:33Z","timestamp":1591212153000},"page":"100714","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"special_numbering":"C","title":["Current management strategies for polycythemia vera and essential thrombocythemia"],"prefix":"10.1016","volume":"42","author":[{"given":"Paola","family":"Guglielmelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2020.100714_bb0005","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100714_bb0010","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/leu.2014.35","article-title":"An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2020.100714_bb0015","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","article-title":"Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment","volume":"22","author":"Barosi","year":"2008","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2020.100714_bb0020","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.leu.2404473","article-title":"A unified definition of clinical resistance\/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group","volume":"21","author":"Barosi","year":"2007","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2020.100714_bb0025","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1365-2141.2009.08019.x","article-title":"A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process","volume":"148","author":"Barosi","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2020.100714_bb0030","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia."},{"issue":"Suppl. 5","key":"10.1016\/j.blre.2020.100714_bb0035","doi-asserted-by":"crossref","first-page":"v85","DOI":"10.1093\/annonc\/mdv203","article-title":"Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger","volume":"26","author":"Vannucchi","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2020.100714_bb0040","first-page":"2018","article-title":"Guidelines. Myeloproliferative neoplasms","volume":"2","author":"Guidelines","year":"2018","journal-title":"Versione"},{"key":"10.1016\/j.blre.2020.100714_bb0045","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1056\/NEJMra1406186","article-title":"Myeloproliferative neoplasms","volume":"376","author":"Spivak","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100714_bb0050","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/bjh.15648","article-title":"A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline","volume":"184","author":"McMullin","year":"2019","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.blre.2020.100714_bb0055","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/bjh.12986","article-title":"Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia","volume":"167","author":"Harrison","year":"2014","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.blre.2020.100714_bb0060","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00508-018-1359-3","article-title":"Austrian recommendations for the management of polycythemia vera","volume":"130","author":"Burgstaller","year":"2018","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.blre.2020.100714_bb0065","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.clml.2015.07.650","article-title":"Evolving therapeutic options for Polycythemia Vera: perspectives of the Canadian Myeloproliferative Neoplasms group","volume":"15","author":"Sirhan","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2020.100714_bb0070","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ajh.23694","article-title":"Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients","volume":"89","author":"Barbui","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2020.100714_bb0075","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/ajh.23585","article-title":"Masked polycythemia Vera (mPV): results of an international study","volume":"89","author":"Barbui","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2020.100714_bb0080","doi-asserted-by":"crossref","first-page":"e337","DOI":"10.1038\/bcj.2015.64","article-title":"Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis","volume":"5","author":"Barbui","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2020.100714_bb0085","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJM197406132902419","article-title":"Bone-marrow responses in polycythemia vera","volume":"290","author":"Prchal","year":"1974","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100714_bb0090","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2008.113","article-title":"Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal","volume":"22","author":"Vannucchi","year":"2008","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2020.100714_bb0095","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1038\/leu.2008.233","article-title":"Genetic complexity of myeloproliferative neoplasms","volume":"22","author":"Kralovics","year":"2008","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2020.100714_bb0100","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in Myeloproliferative Neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100714_bb0105","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100714_bb0110","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1182\/blood-2010-11-316810","article-title":"Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations","volume":"117","author":"Passamonti","year":"2011","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100714_bb0115","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/ajh.22063","article-title":"The JAK2 exon 12 mutations: a comprehensive review","volume":"86","author":"Scott","year":"2011","journal-title":"Am J Hematology"},{"issue":"11","key":"10.1016\/j.blre.2020.100714_bb0120","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1080\/10428194.2017.1300892","article-title":"Evaluation of serum erythropoietin values as defined by 2016 World Health Organization criteria for the diagnosis of polycythemia vera","volume":"58","author":"Silver","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2020.100714_bb0125","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1182\/blood-2011-11-393819","article-title":"Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome","volume":"119","author":"Barbui","year":"2012","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100714_bb0130","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1182\/blood-2007-12-128454","article-title":"The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis and primary myelofibrosis: an alternative proposal","volume":"112","author":"Spivak","year":"2008","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100714_bb0135","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100714_bb0140","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1182\/blood-2017-01-761999","article-title":"Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis","volume":"129","author":"Guglielmelli","year":"2017","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100714_bb0145","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","article-title":"Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms","volume":"127","author":"Milosevic Feenstra","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100714_bb0150","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood-2015-07-661983","article-title":"Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients","volume":"127","author":"Cabagnols","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100714_bb0155","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2015-10-674101","article-title":"Closing the gap: genetic landscape of MPN","volume":"127","author":"Harrison","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100714_bb0160","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.3324\/haematol.2010.026708","article-title":"Comparison of different criteria for the diagnosis of primary myelofibrosis reveals limited clinical utility for measurement of serum lactate dehydrogenase","volume":"95","author":"Beer","year":"2010","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2020.100714_bb0165","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/leu.2017.181","article-title":"CHIP, ICUS, CCUS and other four-letter words","volume":"31","author":"Bejar","year":"2017","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2020.100714_bb0170","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100714_bb0175","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary Myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100714_bb0180","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","article-title":"MIPSS70+ version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary Myelofibrosis","volume":"36","author":"Tefferi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100714_bb0185","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3324\/haematol.2018.206151","article-title":"State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019","volume":"104","author":"McLornan","year":"2019","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2020.100714_bb0190","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1038\/leu.2017.169","article-title":"A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2020.100714_bb0195","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2020.100714_bb0200","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","article-title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia","volume":"1","author":"Tefferi","year":"2016","journal-title":"Bloood Advances"},{"key":"10.1016\/j.blre.2020.100714_bb0205","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.1002\/ajh.24583","article-title":"The effect of arterial hypertension on thrombosis in low-risk polycythemia vera","volume":"92","author":"Barbui","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2020.100714_bb0210","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100714_bb0215","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","article-title":"Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera","volume":"109","author":"Landolfi","year":"2007","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100714_bb0220","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in Polycythemia Vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100714_bb0225","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/blood-2015-04-638593","article-title":"White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study","volume":"126","author":"Barbui","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100714_bb0230","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1200\/JCO.2007.15.3569","article-title":"Leukocytosis and risk stratification assessment in essential thrombocythemia","volume":"26","author":"Carobbio","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100714_bb0235","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1182\/blood-2008-04-153783","article-title":"Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia","volume":"112","author":"Carobbio","year":"2008","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100714_bb0240","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients","volume":"117","author":"Carobbio","year":"2011","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100714_bb0245","series-title":"Leukocytosis and thrombosis in essential Thrombocythemia and Polycythemia Vera: A systematic review and meta-analysis blood advances","author":"Carobbio","year":"2019"},{"key":"10.1016\/j.blre.2020.100714_bb0250","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1182\/blood-2009-02-206797","article-title":"Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?","volume":"114","author":"Barbui","year":"2009","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100714_bb0255","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2141.2006.06430.x","article-title":"The haematocrit and platelet target in polycythemia vera","volume":"136","author":"Di Nisio","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2020.100714_bb0260","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2012-04-424911","article-title":"Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort","volume":"120","author":"Campbell","year":"2012","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100714_bb0265","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/ajh.21730","article-title":"Polycythemia vera-associated acquired von Willebrand syndrome despite near-normal platelet count","volume":"85","author":"Tefferi","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2020.100714_bb0270","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00277-016-2826-4","article-title":"Management of extreme thrombocytosis in myeloproliferative neoplasms: an international physician survey","volume":"96","author":"Koren-Michowitz","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2020.100714_bb0275","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an international prognostic score of thrombosis in World Health Organization\u2013essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100714_bb0280","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1038\/bcj.2015.94","article-title":"Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia","volume":"5","author":"Barbui","year":"2015","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.blre.2020.100714_bb0285","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/ejh.12275","article-title":"External validation and clinical evaluation of the International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in a large cohort of Chinese patients","volume":"92","author":"Fu","year":"2014","journal-title":"European Journal of Haematology"},{"key":"10.1016\/j.blre.2020.100714_bb0290","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/ajh.24293","article-title":"Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET-thrombosis) in 585 Mayo clinic patients","volume":"91","author":"Haider","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2020.100714_bb0295","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia","volume":"123","author":"Rotunno","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100714_bb0300","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100714_bb0305","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1182\/blood-2014-08-596676","article-title":"Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia","volume":"124","author":"Finazzi","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100714_bb0310","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","article-title":"Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project","volume":"121","author":"Barosi","year":"2013","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100714_bb0315","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2141.2010.08430.x","article-title":"Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance\/intolerance to hydroxycarbamide in essential thrombocythaemia","volume":"152","author":"Hern\u00e1ndez-Boluda","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2020.100714_bb0320","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1038\/s41375-018-0199-5","article-title":"Evidence- and consensus-based recommendations for phlebotomy in polycythemia vera","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2020.100714_bb0325","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.leukres.2017.01.032","article-title":"Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy","volume":"56","author":"Verstovsek","year":"2017","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2020.100714_bb0330","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/eurheartj\/ehy813","article-title":"Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials","volume":"40","author":"Mahmoud","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.blre.2020.100714_bb0335","first-page":"132","article-title":"Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols","volume":"23","author":"Berk","year":"1986","journal-title":"Semin Hematol"},{"key":"10.1016\/j.blre.2020.100714_bb0340","first-page":"167","article-title":"Long-term management of polycythemia vera with hydroxyurea: a progress report","volume":"23","author":"Kaplan","year":"1986","journal-title":"Semin Hematol"},{"key":"10.1016\/j.blre.2020.100714_bb0345","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/ajh.24851","article-title":"A re-appraisal of the benefit-risk profile of Hydroxyurea in polycythemia vera: a propensity-matched study","volume":"92","author":"Barbui","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2020.100714_bb0350","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-018-0161-9","article-title":"Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera","volume":"8","author":"Barbui","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2020.100714_bb0355","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJM198102193040801","article-title":"Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy","volume":"304","author":"Berk","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100714_bb0360","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","article-title":"Treatment of Polycythemia Vera with Hydroxyurea and Pipobroman: final results of a randomized trial initiated in 1980","volume":"29","author":"Kiladjian","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100714_bb0365","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2011.34.7542","article-title":"Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms","volume":"29","author":"Bj\u00f6rkholm","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100714_bb0370","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-017-0038-3","article-title":"Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data","volume":"8","author":"Ghirardi","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2020.100714_bb0375","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2018-99-118715","article-title":"Evidence for superior efficacy and disease modification after three years of prospective randomized controlled treatment of Polycythemia Vera patients with Ropeginterferon Alfa-2b vs. HU\/BAT","volume":"132","author":"Gisslinger","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100714_bb0380","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/2040620710394474","article-title":"JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment","volume":"2","author":"Vannucchi","year":"2011","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.blre.2020.100714_bb0385","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2V617F mutation in patients with polycythemia vera or essential thrombocythemia","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100714_bb0390","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","article-title":"Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden","volume":"21","author":"Vannucchi","year":"2007","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2020.100714_bb0395","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/leu.2015.326","article-title":"Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone","volume":"30","author":"Kiladjian","year":"2016","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2020.100714_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(17)30030-3","article-title":"Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial","volume":"4","author":"Masarova","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2020.100714_bb0405","first-page":"128","article-title":"Interim analysis of the Myeloproliferative disorders research consortium (MPD-RC) 112 global phase III trial of front line Pegylated interferon alpha-2a vs. Hydroxyurea in high risk Polycythemia Vera and Essential Thrombocythemia","volume":"479A","author":"Mascarenhas","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100714_bb0410","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/bjh.14289","article-title":"Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study","volume":"175","author":"Alimam","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2020.100714_bb0415","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/bjh.13886","article-title":"Frequency and prognostic value of resistance\/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera","volume":"172","author":"Alvarez-Larr\u00e1n","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2020.100714_bb0420","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2017.165126","article-title":"No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from ECLAP and CYTO-PV clinical trials","volume":"102","author":"Barbui","year":"2017","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2020.100714_bb0425","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/ajh.24607","article-title":"Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management","volume":"92","author":"Tefferi","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2020.100714_bb0430","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of Polycythemia Vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.blre.2020.100714_bb0435","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study","volume":"18","author":"Passamonti","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2020.100714_bb0440","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3324\/haematol.2016.143644","article-title":"Ruxolitinib versus best available therapy in patients with Polycythemia Vera: 80 week follow up from the RESPONSE trial","volume":"101","author":"Verstovsek","year":"2016","journal-title":"Haematologica."},{"issue":"9","key":"10.1016\/j.blre.2020.100714_bb0445","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1007\/s00277-018-3365-y","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial","volume":"97","author":"Griesshammer","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2020.100714_bb0450","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1200\/JCO.2015.62.9337","article-title":"Symptomatic profiles of patients with Polycythemia Vera: implications of inadequately controlled disease","volume":"34","author":"Geyer","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100714_bb0455","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/ejh.12707","article-title":"Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy","volume":"97","author":"Mesa","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2020.100714_bb0460","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.14382","article-title":"The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF)","volume":"176","author":"Mesa","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2020.100714_bb0465","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00277-017-2994-x","article-title":"Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study","volume":"96","author":"Vannucchi","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2020.100714_bb0470","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s00277-017-3225-1","article-title":"Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies","volume":"97","author":"Kiladjian","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2020.100714_bb0475","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100714_bb0480","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100714_bb0485","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","article-title":"Anagrelide compared to hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET study, a randomized controlled trial","volume":"121","author":"Gisslinger","year":"2013","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100714_bb0490","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/bjh.15824","article-title":"A phase III randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia \u2013 the TEAM-ET 2\u00b70 trial","volume":"185","author":"Gisslinger","year":"2019","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.blre.2020.100714_bb0495","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3324\/haematol.2012.083097","article-title":"Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid\u00ae: efficacy and long-term safety study","volume":"99","author":"Gugliotta","year":"2013","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2020.100714_bb0500","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3324\/haematol.2016.146654","article-title":"Antiplatelet therapy versus observation in low-risk essential thrombocythemia with CALR mutation","volume":"101","author":"Alvarez-Larran","year":"2016","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2020.100714_bb0505","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2010-01-263319","article-title":"Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia","volume":"116","author":"Alvarez-Larran","year":"2010","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100714_bb0510","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1182\/blood-2009-08-236679","article-title":"The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy","volume":"115","author":"Dragani","year":"2010","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100714_bb0515","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood-2011-06-359224","article-title":"Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target","volume":"119","author":"Pascale","year":"2012","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100714_bb0520","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-018-0078-3","article-title":"The aspirin regimens in essential Thrombocythemia (ARES) phase II randomized trial design: implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting","volume":"8","author":"De Stefano","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2020.100714_bb0525","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.6004\/jnccn.2017.0157","article-title":"NCCN Guidelines insights: Myeloproliferative Neoplasms, version 2","volume":"15","author":"Mesa","year":"2017","journal-title":"2018 J Natl Compr Canc Netw"},{"key":"10.1016\/j.blre.2020.100714_bb0530","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/bjh.15647","article-title":"A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis","volume":"184","author":"McMullin","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2020.100714_bb0535","doi-asserted-by":"crossref","first-page":"E200","DOI":"10.1002\/ajh.23809","article-title":"Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European leukemia net study","volume":"89","author":"Martinelli","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2020.100714_bb0540","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s11739-010-0413-6","article-title":"Splanchnic vein thrombosis: clinical presentation, risk factors and treatment","volume":"5","author":"De Stefano","year":"2010","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.blre.2020.100714_bb0545","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/bjh.12461","article-title":"Splanchnic vein thrombosis in myeloproliferative neoplasms","volume":"162","author":"Sekhar","year":"2013","journal-title":"Brit J Haematol"},{"key":"10.1016\/j.blre.2020.100714_bb0550","doi-asserted-by":"crossref","first-page":"5617","DOI":"10.1182\/blood-2008-12-196014","article-title":"JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis","volume":"113","author":"Dentali","year":"2009","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2020.100714_bb0555","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jhep.2019.02.015","article-title":"Current knowledge in pathophysiology and management of Budd-Chiari syndrome and non-cirrhotic non-tumoral splanchnic vein thrombosis","volume":"71","author":"Hernandez-Gea","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.blre.2020.100714_bb0560","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1182\/blood-2011-09-376517","article-title":"Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis","volume":"120","author":"Smalberg","year":"2012","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100714_bb0565","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.thromres.2014.04.032","article-title":"Treatment of thromboembolic events coincident with the diagnosis of myeloproliferative neoplasms: a physician survey","volume":"134","author":"Ellis","year":"2014","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2020.100714_bb0570","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-018-0100-9","article-title":"Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018","volume":"8","author":"Finazzi","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2020.100714_bb0575","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-018-0151-y","article-title":"Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases","volume":"8","author":"De Stefano","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2020.100714_bb0580","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/ajh.24614","article-title":"Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms","volume":"92","author":"Pieri","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2020.100714_bb0585","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1182\/blood-2008-11-191544","article-title":"The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome","volume":"113","author":"Sozer","year":"2009","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100714_bb0590","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1182\/blood-2010-07-297598","article-title":"Endothelial progenitor cells are clonal and exhibit JAK2V617F mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms","volume":"117","author":"Teofili","year":"2011","journal-title":"Blood."},{"key":"10.1016\/j.blre.2020.100714_bb0595","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015277","article-title":"High frequency of endothelial Colony forming cells Marks a non-active Myeloproliferative neoplasm with high risk of splanchnic vein thrombosis","volume":"5","author":"Rosti","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.blre.2020.100714_bb0600","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2012-01-404889","article-title":"Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation","volume":"121","author":"Rosti","year":"2013","journal-title":"Blood."}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X20300643?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X20300643?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:25:20Z","timestamp":1759436720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X20300643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":120,"alternative-id":["S0268960X20300643"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2020.100714","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current management strategies for polycythemia vera and essential thrombocythemia","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2020.100714","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100714"}}